Similar Search Results

Expected Profits and the Scientific Novelty of Innovation

Dranove, David; Garthwaite, Craig; Hermosilla, Manuel - 2022

Innovation policy involves trading off monopoly output and pricing in the short run in exchange for incentives for …

Persistent link: https://www.econbiz.de/10013309194

The U.S. Patent System in Transition : Policy Innovation and the Innovation Process

Jaffe, Adam B. - 2021

relating to patenting, robust conclusions regarding the empirical consequences for technological innovation of changes in …

Persistent link: https://www.econbiz.de/10013226916

Opening Up Military Innovation : Causal Effects of Reforms to U.S. Defense Research

T. Howell, Sabrina; Rathje, Jason; Van Reenen, John; … - 2022

There is little econometric study of how governments should procure innovation. One choice facing policymakers is …” approach). We exploit a natural experiment in the widely emulated Small Business Innovation Research (SBIR) program. From 2018 … commercial innovation measured by VC funding and patenting. By contrast, Conventional awards have no effects on these outcomes …

Persistent link: https://www.econbiz.de/10014241294

The Impact of Public and Private Research Support on Premature Cancer Mortality and Hospitalization in the U.S., 1999-2013

Lichtenberg, Frank R. - 2017

We use data from PubMed and other sources to examine the impact of public and private research support on premature (before ages 75, 65, and 55) cancer mortality and hospitalization, by estimating difference-in-differences models based on longitudinal, cancer-site-level data on about 30 cancer...

Persistent link: https://www.econbiz.de/10012960774

German-Jewish Emigres and U.S. Invention

Moser, Petra - 2014

' effects on chemical innovation in the U.S. we compare changes in patenting by U.S. inventors in research fields of émigrés ….S. invention. Inventor-level data indicate that émigrés encouraged innovation by attracting new researchers to their fields, rather …

Persistent link: https://www.econbiz.de/10013057399

The Role of Assets in Place : Loss of Market Exclusivity and Investment

Higgins, Matthew John; Kronlund, Mathias; Park, Ji Min; … - 2022

We utilize a novel identification strategy to analyze the impact of assets in place on firms' decisions for future projects. We exploit the context in the pharmaceutical industry, where the loss of market exclusivity for a branded drug can be used to separate the impact of cash flows generated...

Persistent link: https://www.econbiz.de/10013406834

The Future of Drug Development : The Economics of Pharmacogenomics

Vernon, John A.; Hughen, W. Keener; Vernon, John A. - 2021

This paper models how the evolving field of pharmacogenomics (PG), which is the science of using genomic markers to predict drug response, may impact drug development times, attrition rates, costs, and the future returns to research and development (R&D). While there still remains an abundance...

Persistent link: https://www.econbiz.de/10013311658

The Cost of Us Pharmaceutical Price Reductions : A Financial Simulation Model of R&D Decisions

Abbott, Thomas A.; Vernon, John A. - 2021

Previous empirical studies that have examined the links between pharmaceutical price controls, profits, cash flows, and investment in research and development (R&D) have been largely based on retrospective statistical analyses of firm- and/or industry-level data. These studies, which have...

Persistent link: https://www.econbiz.de/10013227913

Private and Social Returns to R&D : Drug Development and Demographics

Benmelech, Efraim; Eberly, Janice; Krieger, Joshua; … - 2022

Investment in intangible capital—in particular, research and development—increased dramatically since the 1990s. However, productivity growth remains sluggish in recent years. One potential reason is that a significant share of the increase in intangible investment is geared toward consumer...

Persistent link: https://www.econbiz.de/10014264816

Technology Diffusion and Productivity Growth in Health Care

Skinner, Jonathan S. - 2012

Inefficiency in the U.S. health care system has often been characterized as quot;flat of the curvequot; spending providing little or no incremental value. In this paper, we draw on macroeconomic models of diffusion and productivity to better explain the empirical patterns of outcome improvements...

Persistent link: https://www.econbiz.de/10012754821